Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|July 24, 2008
Wolters Kluwer and Nielsen to provide new data on consumers' Rx buying behavior
Alliance is designed to enable more effective product messages.
Advertisement
What drives consumers to purchase pharmaceuticals-in-store merchandising, physician recommendations, managed care, or TV and Internet advertising? Answers to these questions will be available through a new service called
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
2
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
3
FDA Approves Onswik Weekly Insulin for Adults With T2D
4
Conflicting Measles Reports Perpetuate as Cases Continue to Rise
5